MWMatthew F. Wipperman

Matthew F. Wipperman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthew F. Wipperman has a total of 366 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Concerted changes in the pediatric single-cell intestinal ecosystem before and after anti-TNF blockade

    by Hengqi Betty Zheng, Benjamin A Doran, Kyle Kimler, Alison Yu, Victor Tkachev, Veronika Niederlova, Kayla Cribbin, Ryan Fleming, Brandi Bratrude, Kayla Betz, et al.

    Crohn’s disease is an inflammatory bowel disease (IBD) commonly treated through anti-TNF blockade. However, most patients still relapse and inevitably progress. Comprehensive single-cell RNA-sequencing (scRNA-seq) atlases have largely sampled patients with established treatment-refractory IBD, limiting our understanding of which cell types, subsets, and states at diagnosis anticipate disease severity and response to treatment. Here, through combining clinical, flow cytometry, histology, and scRNA-seq methods, we profile diagnostic human biopsies from the terminal ileum of treatment-naive pediatric patients with Crohn’s disease (pediCD; n = 14), matched repeat biopsies (pediCD-treated; n = 8) and from non-inflamed pediatric controls with functional gastrointestinal disorders (FGIDs; n = 13). To resolve and annotate epithelial, stromal, and immune cell states among the 201,883 baseline single-cell transcriptomes, we develop a principled and unbiased tiered clustering approach, ARBOL. Through flow cytometry and scRNA-seq, we observe that treatment-naive pediCD and FGID have similar broad cell type composition. However, through high-resolution scRNA-seq analysis and microscopy, we identify significant differences in cell subsets and states that arise during pediCD relative to FGID. By closely linking our scRNA-seq analysis with clinical meta-data, we resolve a vector of T cell, innate lymphocyte, myeloid, and epithelial cell states in treatment-naive pediCD (pediCD-TIME) samples, which can distinguish patients along the trajectory of disease severity and anti-TNF response. By using ARBOL with integration, we position repeat on-treatment biopsies from our patients between treatment-naive pediCD and on-treatment adult CD. We identify that anti-TNF treatment pushes the pediatric cellular ecosystem toward an adult, more treatment-refractory state. Our study jointly leverages a treatment-naive cohort, high-resolution principled scRNA-seq data analysis, and clinical outcomes to understand which baseline cell states may predict Crohn’s disease trajectory.

  • Open Access

    Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

    by Jennifer D. Hamilton, Manuel A. R. Ferreira, Wei Keat Lim, Carlo Sidore, Matthew F. Wipperman, Wenzhen Ge, Xue Song, Changming Xia, Julie E. Horowitz, Andrea T. Hooper, et al.

    Background: It has long been appreciated that multiple allergic/atopic conditions (type‐2‐inflammation‐associated diseases, T2IDs) often appear in the same individual, suggesting a shared systemic immune deviation. Emerging molecular and clinical investigations of interleukin (IL)4/IL13 blockade with the fully‐human antibody dupilumab suggest that many are driven by over‐activation of the IL4/IL13 pathway, manifesting differently in distinct tissues. Methods and Results: We performed comprehensive quantitative analyses using several large, independent datasets (including real‐world and clinical trial datasets) to confirm that many T2IDs—including asthma, atopic dermatitis, eosinophilic esophagitis, nasal polyps, prurigo nodularis—are highly interrelated based on co‐prevalence, genetic predispositions, and transcriptomic signatures driven by over‐activation of the IL4/IL13 pathway. We also summarize extensive clinical trial data showing that these T2IDs also share uniformly impressive clinical responses to dual IL4/IL13 blockade with dupilumab. Conclusions: While highly consistent with previous data and observations, this is the first systematic comparison of these types of data across multiple T2IDs, using a rigorous quantitative assessment of the largest datasets evaluated to date. Many T2IDs are not only highly interrelated and comorbid, but share transcriptomic signatures and genetic predispositions that suggest they all share over‐activation of the IL4/IL13 pathway as a key causative driver, consistent with and explaining their uniform clinical responsiveness to dual IL4/IL13 blockade. These genetic and transcriptomic signatures may also have utility for identifying other diseases mediated by IL4/IL13 or T2‐mediated subpopulations of heterogenous inflammatory diseases.


  • Open Access

    Validity of a Wearable Digital Insole for Assessing Gait ON and OFF in Parkinson's Disease

    by Deborah A. Hall, Kimberly Kwei, Rolando J. Acosta, Bharatkumar Koyani, Erin Robertson, Pratyush Rai, Roland Barge, Emily Timm, Nicollette L. Purcell, Natasha Desai, et al.

    Objective: Gait impairment is a distinctive symptom of Parkinson's disease that negatively impact mobility. We assessed the validity of wearable digital insoles against a validated reference gait analysis system for measuring select gait characteristics in patients with Parkinson's disease. Methods: A comparative analysis between digital insoles (Moticon ReGo Insole) and the GAITRite system was conducted in patients with Parkinson's disease. Patients were assessed in both the OFF and ON medication states. Gait characteristics were measured simultaneously with both systems during two 10 m walk tests. Patients also completed a patient experience survey following the use of the digital insoles. Results: Overall, 21 patients with Parkinson's disease were included in the study. Analytical validation for gait cadence, speed, and stride length showed excellent agreement (intraclass correlation coefficients between 0.93–0.97) in both the OFF and ON states. Stance, swing, and double support times exhibited lower validity with moderate agreement (intraclass correlation coefficients from 0.48–0.57). Gait speed and stride length were significantly associated with scores on the Movement Disorders Society's Unified Parkinson's Disease Rating Scale ( p = 0.0085 and 0.013, respectively). Mean differences in all parameters measured with the insoles, except cadence, were significantly different between OFF and ON states ( p < 0.003). The majority of patients liked wearing the digital insoles and found them comfortable and user‐friendly. Interpretation: These findings support the validity of Moticon ReGo digital insoles for the assessment of several important gait characteristics in Parkinson's disease.


  • Open Access

    Identification of alkaline phosphatase as a putative biomarker of anti-NGF treatment-associated arthropathies: Machine learning-assisted analyses of clinical trial data

    by Matthew F. Wipperman, Peter J. Ehmann, Debra A.G. McIntyre, Chen Guang Wang, Haitao Gao, Poulabi Banerjee, Kei Ogawa, Yoshiteru Ushirogawa, Erica Chio, Dateng Li, et al.

  • The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma

    by Seblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, Sivan Harel, Kaitlyn Gayvert, Dylan Birchard, Matthew F. Wipperman, Dave Singh, Andrea T. Hooper, George Scott, et al.

    Biologics targeting interleukin-4 receptor subunit α (IL-4Rα) and interleukin-33 (IL-33) have demonstrated clinical efficacy in asthma, highlighting the importance of IL-4, IL-13, and IL-33 in respiratory diseases. Despite this, few studies have linked preclinical models to human diseases or evaluated disease biology in clinical trials. To address these gaps, we evaluated transcriptional, cellular, and pathophysiological processes driven by IL-4/IL-13 and IL-33 using human innate cells in vitro, a mouse model of airway inflammation, and a bronchial allergen challenge (BAC) in house dust mite (HDM)–sensitized individuals with mild asthma. Our findings in mice revealed that the prophylactic blockade of IL-4/IL-13, but not IL-33, prevented the initiation of HDM-induced type 2 inflammation, whereas blocking IL-4Rα or IL-33 during peak inflammation ameliorated airway inflammation and remodeling. Each pathway had unique and overlapping effects on airway inflammation and remodeling, with combination blockade showing no additional benefit. Initiating either monotherapy during severe, mixed inflammation resulted in partial efficacy, whereas a combination of these two treatments led to a substantial reduction in airway inflammation and remodeling in sensitized mice. Some of these mechanistic observations translated to a human BAC model, where blocking IL-4Rα or IL-33 alone suppressed gene expression in sputum and circulating biomarkers. As observed in mice, combination treatment in individuals with allergic asthma did not provide additional benefit compared to monotherapy. Overall, these results provide insight into the differences in targeting IL-4Rα or IL-33 pathways in asthma independently or in combination.


  • Open Access

    Driving novel endpoints and study designs in amyotrophic lateral sclerosis: closer examination of the ALSFRS-R subdomains and a new definition of fast and slow progressors

    by Robert Ellis, William B. Nowell, Nikesh Patel, Matthew F Wipperman, Jiangnan Lyu, Shawn Mishra, Anthony Scotina, Danni Tu, John A. Wagner, Oren Levy

    Amyotrophic lateral sclerosis (ALS) is a motor neuron disease that leads to significant morbidity and mortality, but with substantial variability in the rate of progression [1,2]. A common primary outcome measure used in ALS clinical studies is the ALSFRS-R. Change in this measure may also be used to stratify fast and slow progressors, typically with the assumption of linear decline. Reported limitations of the ALSFRS-R and the assumption of linear slope may hinder novel therapy development. Here we use two distinct populations from a clinical trial database (PRO-ACT) and a natural history registry (ALS TDI) to show that ALSFRS-R fine and gross motor subdomains are more sensitive to disease progression than total score and bulbar and respiratory subdomain scores. We also present a novel non-linear method for defining fast and slow progressors. Together these results may improve demonstration of outcomes in ALS interventional studies using the ALSFRS-R.


  • Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection

    by Christopher D. Petro, Andrea T. Hooper, Avery Peace, Kusha Mohammadi, Will Eagan, Sayda M. Elbashir, Anthony DiPiazza, Daniel Makrinos, Kristen Pascal, Pooja Bandawane, et al.

    Increased use of antiviral monoclonal antibodies (mAbs) for treatment and prophylaxis necessitates better understanding of their impact on endogenous immunity to vaccines and viruses. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presented an opportunity to study immunity in individuals who received antiviral mAbs and were subsequently immunized with vaccines encoding the mAb-targeted viral spike antigen. Here, we describe the impact of administration of an antibody combination, casirivimab plus imdevimab (CAS+IMD), on immune responses to subsequent SARS-CoV-2 vaccination in humans, nonhuman primates, and mice. The presence of CAS+IMD at the time of vaccination led to a specific diminishment of vaccine-elicited pseudovirus neutralizing antibody titers without overall dampening of spike protein–directed immune responses, including antibody, B cell, and T cell responses. The impact on pseudovirus neutralizing titers extended to other therapeutic anti–spike protein antibodies when used as either monotherapy or combination therapy. The specific reduction in pseudovirus neutralizing titers was the result of epitope masking, a phenomenon where specific epitopes are bound by high-affinity antibodies and blocked from B cell recognition. Encouragingly, this reduction in pseudovirus neutralizing titers was reversible with additional booster vaccination. Moreover, by assessing the antiviral immune response in SARS-CoV-2–infected individuals treated therapeutically with CAS+IMD, we demonstrated alteration of antiviral humoral immunity in those who had received mAb therapy, but only in those individuals who had yet to start mounting their natural immune response at the time of mAb treatment. Together, these data demonstrate that antiviral mAbs can alter endogenous humoral immunity during vaccination or infection.


  • Open Access

    Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19

    by Bei Wang, Jacquelynn Golubov, Erin M. Oswald, Patrick Poon, Qiaozhi Wei, Clarissa Lett, Fadi Shehadeh, Matthew Kaczynski, Lewis Oscar Felix, Biswajit Mishra, et al.


  • Top Cited Papers

    Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age

    by Mirna Chehade, Evan S. Dellon, Jonathan M. Spergel, Margaret H. Collins, Marc E. Rothenberg, Robert D. Pesek, Ikuo Hirano, Ruiqi Liu, Elizabeth Laws, Eric Mortensen, et al.

    Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including eosinophilic esophagitis in adults and adolescents. In this phase 3 trial, we randomly assigned, in a 2:2:1:1 ratio, patients 1 to 11 years of age with active eosinophilic esophagitis who had had no response to proton-pump inhibitors to 16 weeks of a higher-exposure or lower-exposure subcutaneous dupilumab regimen or to placebo (two groups) (Part A). At the end of Part A, eligible patients in each dupilumab group continued the same regimen and those in the placebo groups were assigned to higher-exposure or lower-exposure dupilumab for 36 weeks (Part B). At each level of exposure, dupilumab was administered in one of four doses tiered according to baseline body weight. The primary end point was histologic remission (peak esophageal intraepithelial eosinophil count, ≤6 per high-power field) at week 16. Key secondary end points were tested hierarchically. In Part A, histologic remission occurred in 25 of the 37 patients (68%) in the higher-exposure group, in 18 of the 31 patients (58%) in the lower-exposure group, and in 1 of the 34 patients (3%) in the placebo group (difference between the higher-exposure regimen and placebo, 65 percentage points [95% confidence interval {CI}, 48 to 81; P<0.001]; difference between the lower-exposure regimen and placebo, 55 percentage points [95% CI, 37 to 73; P<0.001]). The higher-exposure dupilumab regimen led to significant improvements in histologic, endoscopic, and transcriptomic measures as compared with placebo. The improvements in histologic, endoscopic, and transcriptomic measures between baseline and week 52 in all the patients were generally similar to the improvements between baseline and week 16 in the patients who received dupilumab in Part A. In Part A, the incidence of coronavirus disease 2019, nausea, injection-site pain, and headache was at least 10 percentage points higher among the patients who received dupilumab (at either dose) than among those who received placebo. Serious adverse events were reported in 3 patients who received dupilumab during Part A and in 6 patients overall during Part B. Dupilumab resulted in histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo. The higher-exposure dupilumab regimen also led to improvements in measures of key secondary end points as compared with placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; EoE KIDS ClinicalTrials.gov number, NCT04394351.).


  • Open Access

    Digital wearable insole-based identification of knee arthropathies and gait signatures using machine learning

    by Matthew F Wipperman, Allen Z Lin, Kaitlyn M Gayvert, Benjamin Lahner, Selin Somersan-Karakaya, Xuefang Wu, Joseph Im, Minji Lee, Bharatkumar Koyani, Ian Setliff, et al.

    Gait is impaired in musculoskeletal conditions, such as knee arthropathy. Gait analysis is used in clinical practice to inform diagnosis and monitor disease progression or intervention response. However, clinical gait analysis relies on subjective visual observation of walking as objective gait analysis has not been possible within clinical settings due to the expensive equipment, large-scale facilities, and highly trained staff required. Relatively low-cost wearable digital insoles may offer a solution to these challenges. In this work, we demonstrate how a digital insole measuring osteoarthritis-specific gait signatures yields similar results to the clinical gait-lab standard. To achieve this, we constructed a machine learning model, trained on force plate data collected in participants with knee arthropathy and controls. This model was highly predictive of force plate data from a validation set (area under the receiver operating characteristics curve [auROC] = 0.86; area under the precision-recall curve [auPR] = 0.90) and of a separate, independent digital insole dataset containing control and knee osteoarthritis subjects (auROC = 0.83; auPR = 0.86). After showing that digital insole-derived gait characteristics are comparable to traditional gait measurements, we next showed that a single stride of raw sensor time-series data could be accurately assigned to each subject, highlighting that individuals using digital insoles can be identified by their gait characteristics. This work provides a framework for a promising alternative to traditional clinical gait analysis methods, adds to the growing body of knowledge regarding wearable technology analytical pipelines, and supports clinical development of at-home gait assessments, with the potential to improve the ease, frequency, and depth of patient monitoring.